The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN)

被引:48
作者
Newlands, ES [1 ]
机构
[1] Charing Cross Hosp, Treatment & Screening Ctr Gestat & Trophoblast Ne, London W6 8RF, England
来源
BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY | 2003年 / 17卷 / 06期
关键词
gestational trophoblastic neoplasia; choriocarcinoma; placental site trophoblastic tumour;
D O I
10.1016/S1521-6934(03)00092-0
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Gestational trophoblastic neoplasia (GTN) comprises a spectrum of disease from low-risk disease which can be cured with simple relatively non-toxic treatment, to extremely aggressive tumours which require specialized management. The prognostic variables in patients with GTN are different from those in other gynaecological malignancies, and the major adverse prognostic variables include long interval from antecedent pregnancy, high concentrations of the pregnancy hormone, human chorionic gonadotrophin, metastases in brain and liver and failure of prior treatment. Patients who relapse after their prior treatment can also be categorized into different risk groups. Salvage treatment can vary from single agent actinomycin D to combination chemotherapy and, in selected cases, surgery. With appropriate management, the majority of patients can achieve long-term remission and, in most cases, preserve fertility. The late side-effects of more intensive treatment are a small risk of inducing second tumours and also of bringing forward the age of menopause.
引用
收藏
页码:905 / 923
页数:19
相关论文
共 28 条
  • [1] Balaram P, 1997, J CANCER RES CLIN, V123, P161
  • [2] EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients
    Bower, M
    Newlands, ES
    Holden, L
    Short, D
    Brock, C
    Rustin, GJS
    Begent, RHJ
    Bagshawe, KD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2636 - 2643
  • [3] Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years
    Bower, M
    Rustin, GJS
    Newlands, ES
    Holden, L
    Short, D
    Foskett, M
    Bagshawe, KD
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (08) : 1204 - 1207
  • [4] Pemetrexed disodium, a novel antifolate with multiple targets
    Curtin, N. J.
    Hughes, A. N.
    [J]. LANCET ONCOLOGY, 2001, 2 (05) : 298 - 306
  • [5] Drevs J, 2000, CANCER RES, V60, P4819
  • [6] Phase II trial of gemcitabine in refractory germ cell tumors
    Einhorn, LH
    Stender, MJ
    Williams, SD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 509 - 511
  • [7] FISHER RA, 1997, GESTATIONAL TROPHOBL, pCH2
  • [8] HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR REFRACTORY METASTATIC GESTATIONAL TROPHOBLASTIC DISEASE
    GIACALONE, PL
    BENOS, P
    DONNADIO, D
    LAFFARGUE, F
    [J]. GYNECOLOGIC ONCOLOGY, 1995, 58 (03) : 383 - 385
  • [9] Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial
    Hensley, ML
    Maki, R
    Venkatraman, E
    Geller, G
    Lovegren, M
    Aghajanian, C
    Sabbatini, P
    Tong, W
    Barakat, R
    Spriggs, DR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) : 2824 - 2831
  • [10] Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the eastern cooperative oncology group
    Hinton, S
    Catalano, P
    Einhorn, LH
    Leohrer, PJ
    Kuzel, T
    Vaughn, D
    Wilding, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1859 - 1863